

Pressure Biosciences, Inc. (P BIO) Benefits From Surge In Life Sciences and Medical Technology Markets

Pressure Biosciences (P BIO) is a company at forefront of new technologies in the life sciences market.

SALT LAKE CITY, UT, USA, September 29, 2014 /EINPresswire.com/ -- [Pressure Biosciences \(P BIO\)](#) is a company at forefront of new technologies in the life sciences market. P BIO builds machines that use a special, high-pressure technology, something they call PCT (Pressure Cycling Technology). These machines use pressure to break apart larger tissue samples and extract molecules - think of a sand sifter breaking apart a larger piece of earth into much finer sand particles to extract what's inside. P BIO's machines do just that with molecules, and are sold to laboratories that prepare samples which are then used in such areas as forensics research, drug design, and biomarker discovery, depending on the laboratory or clinic.



P BIO, which is trading at a .31 cents per share and maintains an average volume of 43K, has clearly received a boost from the booming biotech market. As biotech companies grow in relevance, raising a staggering 6.4 billion in investor capital last year, the interdependence of the medical industry continues to reveal itself. Tertiary markets like life sciences sprout new companies, products, and technologies, just like P BIO's pressure technology machines, that are borne out of the necessity of supporting pharmaceuticals and biotechs, however, many of these smaller companies have emerged to make a name for themselves.

Before a complex new biologic drug arrives on the market for one of the biotechs, medical technicians will require the tools to develop it and test its readiness for consumers, which is where P BIO comes in. The company retains the experience of numerous years in the industry, but hit its stride in the last year and a half with the widespread development and marketing of its PCT technologies.

Overall revenue was up 9% between Q1 2013 and the same time frame in 2014, while product and service revenue climbed an impressive 82% as the company began to sell to laboratories at a more diligent pace. Consumables revenue grew by an astounding 101% while operating costs were almost identical to 2013's figures, which is always a good sign. A recent announcement regarding the shipment and purchase of its latest PCT-based instrument system, Barozyme HT48, is a strong indicator that revenues will again be on the rise in the fourth quarter of 2014.

In addition to fostering products that make its brand synonymous with ingenuity and quality, Pressure Biosciences also happens to be benefiting from the upward swing of a few peripheral companies.

Thermal Fisher Scientific (TMO), trading at 121.36 with a 48.47B market cap, is an industry giant predicted by The Wall Street Journal to increase in value by 20% over the next year. With an estimated 2014 revenue of nearly \$17 billion and over 20 major acquisitions under its belt in the last five years, TMO serves as a pulse check for the financial status of the entire life sciences market, and its numbers represent the increased livelihood of this set of companies.

Another prime example of a robust company in this field is Medtronic (MDT), which recently received a boost from its Reveal LINQ device, an unimaginably small heart monitor used to measure electrical activity and can be inserted without surgery. The market for insertable devices designed this small is expected to grow to a half billion dollars by the turn of the decade, as once again, a medical necessity warrants the technology. Medtronic currently trades at 63.34 after a recent minor surge, and with the Reveal LINQ reportedly becoming Medtronic's hottest device, the potential for sustained growth is more than apparent.

Enteromedics Inc. (ETRM), trading at 1.13 with a market cap of roughly 78M, also demonstrates promise in the field of insertable devices, as the company continues to make strides with its VBLOC therapy, a pacemaker-like apparatus that blocks a nerve in the digestive system that controls hunger, thereby acting as a remedy for obesity and metabolic diseases while also improving diabetes control.

ETRM and especially PBIO act as entryways into a life sciences industry marked by medical technologies that combat diseases and serve as necessary research tools. PBIO's devices accomplish sample preparation for labs developing new drugs and researching evidence in rape crimes. All of the positive financial growth reflects the quality of Pressure Bioscience's technologies and the willingness of its clients to invest in PCT technology. With PBIO's market data and overall performance headed in the right direction, the level of confidence demonstrated by PBIO's clients should also extend to investors pursuing the Company as a life sciences stock poised for future success.

Please visit PBIO on Facebook and Twitter.

<https://www.facebook.com/presbiosciences>

<https://twitter.com/PresBioSciences>

Disclaimer:

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements

DISCLAIMER: Seraphim Strategies is a third party publisher. Not a registered

broker/dealer/analyst/adviser, holds no investment licenses and may not sell, offer to sell or offer to buy any security. Market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is not to be interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. For full disclaimer please read <http://tomorrowsbluechips.com/disclaimer/>

Lou Levenstein
Seraphim Strategies
801-988-6474
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2015 IPD Group, Inc. All Right Reserved.